Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period

J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e705-e707. doi: 10.1111/jdv.16443. Epub 2020 Jul 28.

Authors

M Megna¹, G Fabbrocini¹, E Camela¹, E Cinelli¹

Affiliation

¹ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 32277507
DOI: 10.1111/jdv.16443

No abstract available

Publication types

Letter

MeSH terms

Aged
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Thalidomide* / analogs & derivatives
Thalidomide* / therapeutic use
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Thalidomide
apremilast